Silke Jamitzky

492 total citations
9 papers, 390 citations indexed

About

Silke Jamitzky is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Silke Jamitzky has authored 9 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Silke Jamitzky's work include CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (4 papers) and Neuroblastoma Research and Treatments (2 papers). Silke Jamitzky is often cited by papers focused on CAR-T cell therapy research (8 papers), Immunotherapy and Immune Responses (4 papers) and Neuroblastoma Research and Treatments (2 papers). Silke Jamitzky collaborates with scholars based in Germany, Netherlands and France. Silke Jamitzky's co-authors include Claudia Rössig, Bianca Altvater, Sareetha Kailayangiri, Wolfgang Hartmann, Jutta Meltzer, Sonja Schelhaas, Jendrik Hardes, Eva Wardelmann, Uta Dirksen and Constanze Wiek and has published in prestigious journals such as Cancer Research, Scientific Reports and Molecular Therapy.

In The Last Decade

Silke Jamitzky

9 papers receiving 386 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silke Jamitzky Germany	7	296	198	119	75	68	9	390
Jutta Meltzer Germany	8	266 0.9×	181 0.9×	107 0.9×	85 1.1×	57 0.8×	11	372
Charlotte Helena Rivas United States	3	223 0.8×	187 0.9×	63 0.5×	17 0.2×	48 0.7×	6	304
Anandani Nellan United States	8	129 0.4×	58 0.3×	94 0.8×	32 0.4×	48 0.7×	18	265
Monica Epstein United States	3	330 1.1×	149 0.8×	72 0.6×	20 0.3×	131 1.9×	5	395
Caiying Jiang China	5	236 0.8×	130 0.7×	61 0.5×	17 0.2×	55 0.8×	7	277
Dimitrios Alatzoglou Switzerland	2	246 0.8×	198 1.0×	137 1.2×	31 0.4×	63 0.9×	3	409
Manon Pillai United Kingdom	7	359 1.2×	135 0.7×	93 0.8×	33 0.4×	137 2.0×	24	392
Stephen Nabarro United Kingdom	6	331 1.1×	183 0.9×	91 0.8×	19 0.3×	127 1.9×	6	421
Philipp Knopf Germany	5	286 1.0×	201 1.0×	55 0.5×	41 0.5×	36 0.5×	10	357
Adam M. Swartz United States	10	196 0.7×	206 1.0×	126 1.1×	17 0.2×	45 0.7×	18	364

Countries citing papers authored by Silke Jamitzky

Since Specialization

Citations

This map shows the geographic impact of Silke Jamitzky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silke Jamitzky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silke Jamitzky more than expected).

Fields of papers citing papers by Silke Jamitzky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silke Jamitzky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silke Jamitzky. The network helps show where Silke Jamitzky may publish in the future.

Co-authorship network of co-authors of Silke Jamitzky

This figure shows the co-authorship network connecting the top 25 collaborators of Silke Jamitzky. A scholar is included among the top collaborators of Silke Jamitzky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silke Jamitzky. Silke Jamitzky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Jamitzky, Silke, Bianca Altvater, Lisa Richter, et al.. (2024). Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target. Scientific Reports. 14(1). 11935–11935. 1 indexed citations

Kailayangiri, Sareetha, et al.. (2020). Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. Cancers. 12(5). 1075–1075. 84 indexed citations

Kailayangiri, Sareetha, et al.. (2020). Abstract 4999: Evaluation of anti-Gr1 antibody for depletion of MDSC in preclinical NSG mouse models of pediatric sarcoma. Cancer Research. 80(16_Supplement). 4999–4999. 1 indexed citations

Kailayangiri, Sareetha, Bianca Altvater, Stefanie Lesch, et al.. (2019). EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells. Molecular Therapy. 27(5). 933–946. 88 indexed citations

Rössig, Claudia, Sareetha Kailayangiri, Silke Jamitzky, & Bianca Altvater. (2018). Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. Frontiers in Oncology. 8. 513–513. 33 indexed citations

Kailayangiri, Sareetha, Silke Jamitzky, Bianca Altvater, et al.. (2017). Programmed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood & Cancer. 65(1). 40 indexed citations

Kailayangiri, Sareetha, Bianca Altvater, Silke Jamitzky, et al.. (2017). T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. Oncotarget. 9(5). 6536–6549. 34 indexed citations

Kailayangiri, Sareetha, Bianca Altvater, Silke Jamitzky, et al.. (2016). Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology. 6(1). e1250050–e1250050. 91 indexed citations

Jamitzky, Silke, et al.. (2015). Insulin‐like growth factor‐1 receptor (IGF‐1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells. Pediatric Blood & Cancer. 62(11). 1979–1985. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact